Drug Approval Process in Europe - An Outlook
Drug Approval Process in Europe - An Outlook Updated Research Available
RELEASE DATE
22-Dec-2008
22-Dec-2008
REGION
Europe
Europe
Research Code: M2DB-01-00-00-00
SKU: HC01742-EU-MR_06503
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
HC01742-EU-MR_06503
Description
This research deals with the drug approval process in Europe by focussing on the various marketing authorisation procedures, price controls and parallel trading. A snapshot of the biosimilars approval process is also provided along with the key strategic recommendations.
Table of Contents
Executive Summary of the Drug Approval Process in Europe
- Overview of the European Drug Approval Process
Research Methodology for Drug Approval Process in Europe
- The Methodology
- Scope and Objectives
Major Industry Challenges
- Introduction
- Regulatory Challenges in the European Union
Marketing Authorisation Procedures
- Marketing Authorisation Procedures in Europe
- Comparing the Regulatory Systems in Europe and the United States
Overview of the Price Control and Parallel Trading in Europe
- Analysis of Price Control and Parallel Trading
Approval Process for Biosimilars
- Biosimilars in Europe
Key Findings
- Recommendations for the European Drug Approval Process
Decision Support Database
- Number of Biotech Companies
- Number of Biotetchnology Patents-European Patents Office
- Number of Biotechnology Patents - USA Patents and Trade Mark Office
- Government R&D Investment in Biotechnology
- Private Investment in Biotechnology
Related Research
Popular Topics
This research deals with the drug approval process in Europe by focussing on the various marketing authorisation procedures, price controls and parallel trading. A snapshot of the biosimilars approval process is also provided along with the key strategic recommendations.
No Index | No |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | M2DB-01-00-00-00 |
Is Prebook | No |